Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

Clinical trial NCT00679029 · TERMINATED

Trial details

NCT number: NCT00679029
Sponsor: University of Nebraska
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

HER2-negative Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer

Start date: 2008-05-02
Primary completion: 2010-11-18
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.